USFDA okays glucagon pen

November 15, 2019 0 By FM

Xeris Pharma’s Gvoke, a glucagon pen pre-filled device with a liquid stable form of glucagon has been granted approval by the USFDA to treat severe low sugar levels in diabetes patients, the drug maker said.

The condition, called hypoglycemia, can cause acute cognitive impairment. It can occur multiple times a month, can also result in heart disease, seizure and coma in its severe form.